Bionor Pharma’s First Reboost Vacc-4x Study Accepted for Publication in the Vaccine Journal

(Oslo, Norway, 7 August 2013)  Bionor Pharma ASA (OSE: BIONOR) announces that the results from the Company’s first re-boost clinical trial of Vacc-4x have been accepted for publication in the renowned journal Vaccine. The Phase II trial was conducted at Oslo University Hospital and completed in 2010. The trial investigated the effect of re-boosting 22 …

Read more

HIV research by Danish scientists presented at AIDS conference in Kuala Lumpur, Malaysia

Oslo 01.07.2013 – The study was recently presented by Prof. Lars Østergaard from Aarhus University Hospital at Bionor Pharma’s Capital Markets Day in Oslo, 14 June. See article in the Danish newspaper Berlingske 30 June about the research with HDAC Inhibitors in HIV patients, presented at the conference in Kuala Lumpur: http://www.b.dk/nationalt/dansk-gennembrud-i-kampen-mod-hiv# See also information at …

Read more

Bionor Pharma Announces Successful Completion of the First Part of its Phase II Clinical Study Combining the HIV Vaccine Vacc-4x with Celgene’s Immunomodulator Lenalidomide (Revlimid®)

Oslo 13.06.2013 – The highest dose of lenalidomide has been chosen for the second, placebo-controlled part of the study, where a number of HIV patients are ready for screening Bionor Pharma ASA (OSE: BIONOR) announced today that the first part of its phase II clinical study combining the HIV vaccine, Vacc-4x, with Celgene’s immunomodulator, lenalidomide, …

Read more